Infinity DBS IPG
ABBOTT MEDICAL · Decision date Sep 23, 2026
What did the FDA approve?
The FDA's decision record for P140009/S139, dated 2026-09-23, shows approval of a real-time process supplement classified under a change in design, components, specifications or materials. The stated scope is a material change to the encapsulant used in the printed circuit board assembly during manufacture. The affected devices named in the statement are the Proclaim Spinal Cord Stimulator, Proclaim Dorsal Root Ganglion stimulator and Infinity Deep Brain Stimulator implantable pulse generator.
S139 is a supplement to PMA P140009, which the identifier ties to the original approval; it covers a manufacturing material substitution, not a fresh approval of an entire device system. The listing carries product code MHY, the neurology category Stimulator, electrical, implanted, for parkinsonian tremor, and Abbott Medical as applicant. The record does not state encapsulant identity, concentration, process validation results, or separate safety or clinical effectiveness evidence; approval reflects the agency's action on the change.
FDA approval order statement
approval for a material change to the encapsulant used in the printed circuit board assembly (PCBA) during the manufacture of the Proclaim Spinal Cord Stimulator (SCS), Proclaim Dorsal Root Ganglion (DRG) stimulator and Infinity Deep Brain Stimulator (DBS) Implantable Pulse Generator (IPG) devices.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Sep 23, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140009/S139
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- MHY
- Decision code
- APPR
- Decision date
- Sep 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian tremor.
- Applicant
- Abbott Medical
- Product code
- MHY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140009 · Original PMA
BRIO NEUROSTIMULATION SYSTEM
P140009/S139 received
Application receipt date recorded by FDA.
P140009/S140 · Related supplement
Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger
P140009/S139 · FDA decision
Real-Time Process
P140009/S143 · Related supplement
Liberta RC Deep Brain Stimulation (DBS) Implantable Pulse Generator
P140009/S141 · Related supplement
Deep Brain Stimulation (DBS) EPG
P140009/S142 · Related supplement
Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger
P140009/S144 · Related supplement
Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG)
Timeline entries are records held by MedtechLedger for P140009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BRIO NEUROSTIMULATION SYSTEMP140009 | ABBOTT MEDICAL | PMA approval | Jun 12, 2015 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
Deep Brain Stimulation (DBS) EPGP140009/S141 | ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code MHY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 8, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 6, 2026 | FDA | |
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEMP960009/S546 | Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Prestion Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P140009/S139
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records